<DOC>
	<DOC>NCT01466465</DOC>
	<brief_summary>Allergen-specific immunotherapy is the only causal therapy of Immunoglobulin E-induced allergies like allergic rhinoconjunctivitis. Despite progress during the last decades it is limited by a long treatment time and high non-responder frequency. Based on experimental and epidemiological evidences we hypothesize that vitamin D can act as an effective immunomodulatory adjuvant to overcome these limitations.</brief_summary>
	<brief_title>Vitamin D and Grass Pollen Specific Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>written informed consent relative Vitamin D deficiency clinical relevant grass pollen allergy positive intradermal test with grass pollen forced expiratory volume at one second (FEV1) &gt; 70% current specific immunotherapy instable allergic asthma pregnancy and lactation treatment with immunomodulators or immunosuppressive drugs sarcoidosis, chronic diseases, malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>SIT</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>allergic rhinoconjunctivitis</keyword>
</DOC>